InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (18 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
18
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Rawcliffe Adrian, Chief Executive Officer. Director active across 3 companies, notably Adaptimmune Therapeutics PLC. In total, 21 filings have been logged. Split: 0 buy · 18 sells. Total volume traded: €371k. History available since 28 June 2021. The latest transaction was disclosed on 12 August 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Rawcliffe Adrian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
12,700 shares@ US$5.29100.0% of flowCommon StockSEC:0001193125-26-349962:0
42,000 shares@ US$5.9769.5% of flowOrdinary SharesSEC:0001193125-25-314742:0
16,115 shares@ US$6.79100.0% of flowOrdinary SharesSEC:0001193125-25-283619:0
12,700 shares0Ordinary SharesSEC:0000950170-25-108286:0
30,601 shares@ US$0.58085.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004605:0
12,539 shares@ US$0.58792.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003775:0
16,115 shares0Ordinary SharesSEC:0000950170-24-097290:0
9,304 shares@ US$0.792.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-24-004564:0
11,945 shares@ US$0.83672.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-24-003742:0
2,403 shares@ US$0.780.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-097853:0
2,333 shares@ US$0.920.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-075407:0
10,057 shares@ US$1.8585.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-004379:0
13,042 shares@ US$1.74686.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-003534:0
5,073 shares@ US$1.6942.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-001088:0
2,536 shares@ US$1.96891.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-097135:0
2,562 shares@ US$1.631.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-074926:0
11,096 shares@ US$3.191814.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-005053:0
14,362 shares@ US$3.556720.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-004149:0
5,532 shares@ US$4.06429.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-001668:0
2,782 shares@ US$5.1955.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-112179:0
2,794 shares@ US$4.374.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-086385:0
21 of 21 declarations
About Rawcliffe Adrian
Chief Executive Officer at Adaptimmune Therapeutics PLC and Director at Wave Life Sciences Ltd., Rawcliffe Adrian has 20 filings in total. Across the 20 sampled filings between 2021-06-28 and 2025-12-10, the recorded transactions are all disposals, with total sales of EUR 312383 and no purchases.
